1. Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme1. Issue 2 (16th September 2014) Authors: Raccah, Denis; Miossec, Patrick; Esposito, Virginie; Niemoeller, Elisabeth; Cho, Meehyung; Gerich, John Journal: Diabetes/metabolism research and reviews Issue: Volume 31:Issue 2(2015:Feb.) Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease. (2nd August 2022) Authors: Dimachkie, Mazen M.; Barohn, Richard J.; Byrne, Barry; Goker-Alpan, Ozlem; Kishnani, Priya S.; Ladha, Shafeeq; Laforêt, Pascal; Mengel, Karl Eugen; Peña, Loren D.M.; Sacconi, Sabrina; Straub, Volker; Trivedi, Jaya; Van Damme, Philip; van der Ploeg, Ans T.; Vissing, John; Young, Peter; Haack, Kris... Journal: Neurology Issue: Volume 99:Number 5(2022) Page Start: e536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. (October 2014) Authors: Christensen, Mikkel; Miossec, Patrick; Larsen, Bjarne Due; Werner, Ulrich; Knop, Filip K Journal: Expert opinion on drug discovery Issue: Volume 9:Number 10(2014:Oct.) Page Start: 1223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗